About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01459380

Veliparib, Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Study identifier: NCT01459380
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, no more than one previous chemotherapy regimen, no prior treatment with PARP inhibitor

Type of study:

Phase I study

Treatment:

Participants will be in one of two groups:

  • 28-day cycles with veliparib orally on days 1-7 and doxorubicin hydrochloride intravenously and carboplatin intravenously on day 1. (Some patients may also receive bevacizumab intravenously on day 1 and 15.)
  • 28-day cycles with veliparib orally daily and doxorubicin hydrochloride intravenously and carboplatin intravenously on day 1. (Some patients may also receive bevacizumab intravenously on day 1 and 15.)

Study sites:

Colorado
Aurora
University of Colorado Cancer Center - Anschutz Cancer Pavilion
Contact: Susan A. Davidson 720-848-0650

Georgia
Augusta
Georgia Regents University
Contact: Sharad A. Ghamande 706-721-1663 cancer@georgiahealth.edu

Illinois
Chicago
University of Chicago Comprehensive Cancer Center
Contact: Seiko D. Yamada 773-834-7424

Iowa
Iowa City
University of Iowa Hospitals and Clinics
Contact: Koen De Geest 800-237-1225

New York
New York
Memorial Sloan Kettering Cancer Center
Contact: Katherine M. Bell-McGuinn 212-639-7202

Ohio
Cleveland
Case Western Reserve University
Contact: Steven E. Waggoner 800-641-2422

Cleveland Clinic Foundation
Contact: Steven E. Waggoner 800-641-2422

Columbus
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Contact: David M. O'Malley 866-627-7616 osu@emergingmed.com

Mayfield Heights
Hillcrest Hospital Cancer Center
Contact: Steven E. Waggoner 800-641-2422

Oklahoma
Oklahoma City
University of Oklahoma Health Sciences Center
Contact: Robert S. Mannel 405-271-4272 julie-traylor@ouhsc.edu
Principal Investigator: Robert S. Mannel

Pennsylvania
Philadelphia
Gynecologic Oncology Group
Contact: Lisa M. Landrum 405-271-8707 Lisa-landrum@ouhsc.edu

Rhode Island
Providence
Women and Infants Hospital
Contact: Paul A. DiSilvestro 401-274-1122

Page updated 06/08/13

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org